Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

DxTerity secures CE Mark for REDI-Dx radiation biodosimetry test

Published 29 May 2018

DxTerity Diagnostics has secured CE mark for the REDI-Dx radiation biodosimetry test for the quantitative estimation of the absorbed ionizing radiation dose after a nuclear event.

A radiological event, from the use of a nuclear weapon or improvised nuclear device, could potentially expose thousands of individuals to high or moderate levels of radiation that would require immediate medical intervention.

REDI-Dx measures the biological response to radiation and provides individualized estimates of absorbed radiation from a peripheral blood sample. Physicians can use the estimate, in conjunction with radiation dispersal monitoring and clinical signs and symptoms, to prioritize the highly and moderately exposed individuals from the concerned public for medical treatment.

DxTerity CEO and founder Bob Terbrueggen said: “REDI-Dx fulfills a critical unmet need for responding to a mass scale nuclear event. It is the first CE-IVD assay for radiation biodosimetry and is designed to integrate into existing clinical testing infrastructure and read-out on the installed base of ABI 3500 Dx CE instruments.”

The dicentric chromosome assay is the current “gold standard” in Europe and Asia; however, the limited testing capacity, lack of standardization, and 72-hour time to result limits its practicality. REDI-Dx overcomes these limitations with ambient sample shipping, 6-hour assay processing time, and a standardized CE-IVD kit for high throughput testing.

REDI-Dx is the result of a multi-year collaboration between DxTerity, Duke University, the University of Arizona, and Thermo Fisher Scientific; as well as patients and researchers from City of Hope Cancer Center and University of California Los Angeles.

The REDI-Dx® Biodosimetry Test is designed to measure a panel of gene expression markers and estimate individualized levels of absorbed ionizing radiation from a blood sample after a nuclear event.

DxTerity provides services and technologies to partner organizations, such as molecular diagnostic test development and end-to-end management of population-scale genomic studies.

Source: Company Press Release